Quantitative histomorphometry and quantitative polymerase chain reaction (Pcr) as assessment tools for product development

Robert G. Audet, Robert B. Diller, Robert S. Kellar

Research output: Contribution to journalArticle

Abstract

In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device’s success, or a combination therapy’s clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

Original languageEnglish (US)
Pages (from-to)163-174
Number of pages12
JournalMethods in Pharmacology and Toxicology
Volume20
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Bandages
Polymerase Chain Reaction
Skin
Matrix Metalloproteinases
Immunohistochemistry
Gene Expression
Equipment and Supplies
Drug-Eluting Stents
Elastin
Health
Therapeutic Uses
Therapeutics
Interleukin-8
Interleukin-6
Histology
Healthy Volunteers
Collagen
Tumor Necrosis Factor-alpha
Oxygen
Biopsy

Keywords

  • Gene expression
  • Histology
  • Immunohistochemistry
  • Product developmentS
  • qPCR
  • Quantitative histomorphometry
  • Quantitative polymerase chain reaction
  • RT-PCR

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Molecular Medicine
  • Pharmacology (medical)

Cite this

Quantitative histomorphometry and quantitative polymerase chain reaction (Pcr) as assessment tools for product development. / Audet, Robert G.; Diller, Robert B.; Kellar, Robert S.

In: Methods in Pharmacology and Toxicology, Vol. 20, 2015, p. 163-174.

Research output: Contribution to journalArticle

@article{26586046d57a49b6b461ae91d8270cb1,
title = "Quantitative histomorphometry and quantitative polymerase chain reaction (Pcr) as assessment tools for product development",
abstract = "In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device’s success, or a combination therapy’s clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.",
keywords = "Gene expression, Histology, Immunohistochemistry, Product developmentS, qPCR, Quantitative histomorphometry, Quantitative polymerase chain reaction, RT-PCR",
author = "Audet, {Robert G.} and Diller, {Robert B.} and Kellar, {Robert S.}",
year = "2015",
doi = "10.1007/7653_2014_38",
language = "English (US)",
volume = "20",
pages = "163--174",
journal = "Methods in Pharmacology and Toxicology",
issn = "1557-2153",
publisher = "Humana Press",

}

TY - JOUR

T1 - Quantitative histomorphometry and quantitative polymerase chain reaction (Pcr) as assessment tools for product development

AU - Audet, Robert G.

AU - Diller, Robert B.

AU - Kellar, Robert S.

PY - 2015

Y1 - 2015

N2 - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device’s success, or a combination therapy’s clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

AB - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device’s success, or a combination therapy’s clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

KW - Gene expression

KW - Histology

KW - Immunohistochemistry

KW - Product developmentS

KW - qPCR

KW - Quantitative histomorphometry

KW - Quantitative polymerase chain reaction

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=84935828579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935828579&partnerID=8YFLogxK

U2 - 10.1007/7653_2014_38

DO - 10.1007/7653_2014_38

M3 - Article

AN - SCOPUS:84935828579

VL - 20

SP - 163

EP - 174

JO - Methods in Pharmacology and Toxicology

JF - Methods in Pharmacology and Toxicology

SN - 1557-2153

ER -